平消片为主组合方案治疗乳腺增生症临床分析

Clinical Analysis of the Combination of Pingxiao Tablets in the Treatment of Mammary Hyperplasia

目的分析平消片为主组合方案治疗乳腺增生症的临床疗效。方法选取我院2015年1月~2016年12月100例乳腺增生症患者作为观察对象,随机分为观察组和对照组,每组50例。对照组采用三苯氧胺联合平消片的治疗方案;观察组采用托瑞米芬联合平消片的治疗方案。比较两组患者的临床疗效以及不良反应发生率。结果观察组与对照组的治疗有效率分别为92.00%和90.00%,两组相比,差异无统计学意义(P>0.05)。观察组不良反应发生率为6.00%,低于对照组的22.00%,差异具有统计学意义(P<0.05)。结论三苯氧胺联合平消片与托瑞米芬联合平消片在乳腺增生症的临床治疗中均有较好的临床疗效,但托瑞米芬联合平消片的安全性更高,值得在临床中推广使用。

Objective To analyze the clinical effect of Pingxiao tablet combined regimen in the treatment of mammary hyperplasia.Methods 100 patients with breast hyperplasia from January 2015 to December 2016 were randomly divided into observation group and control group with 50 cases in each group.The control group was treated with tamoxifen combined with Pingxiao tablet and the observation group with tolemiphene combined with pingxiao tablet.The clinical efficacy and incidence of adverse reactions were compared between the two groups.Results The effective rates of treatment were 92.00%and 90.00%in the observation group and the control group,respectively,there was no significant difference between the two groups(P>0.05).The incidence of adverse reactions in the observation group was 6.00%,which was lower than that in the control group 22.00%,and the difference was statistically significant(P<0.05).Conclusion The combination of tamoxifen and torreifene in the clinical treatment of hyperplasia of mammary glands has good clinical effect,but the safety of toromifene combined with Ping Xiao tablet is higher.It is worth popularizing in clinical practice.